6JM:F:F-JMDC INC. (EUR)

COMMON STOCK | Health Information Services |

Last Closing

USD 28.6

Change

0.00 (0.00)%

Market Cap

USD 1.93B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

JMDC Inc. provides medical statistics data services in Japan. The company offers medical field big data services; life insurance field big data services; support services for health insurance associations and local government health services; health data platform; and medical institution support services. It serves health insurance unions, pharmaceutical companies, life and non-life insurance companies, research institutions, etc. JMDC Inc. was incorporated in 2002 and is headquartered in Tokyo, Japan. As of October 10, 2023, JMDC Inc. operates as a subsidiary of OMRON Corporation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
L0T:F GE HEALTHCARE TECH.INC.

+1.53 (+1.93%)

USD 35.91B
2HE:F Healthequity Inc

-1.00 (-1.42%)

USD 6.16B
4YC:F M3 INC.

+0.10 (+1.15%)

USD 5.81B
6HL0:F R1 RCM Inc

+0.10 (+0.79%)

USD 5.45B
9EH:F Evolent Health Inc

+0.40 (+1.46%)

USD 3.16B
1KJ:F 10X GENOMICS DL -00001

+2.23 (+11.83%)

USD 2.31B
OC9:F Omnicell Inc

-1.80 (-4.50%)

USD 1.78B
19P:F Phreesia Inc

-0.20 (-0.92%)

USD 1.26B
4LL:F Teladoc Inc

+0.05 (+0.60%)

USD 1.25B
1XZ:F Ping An Healthcare and Technol..

+0.02 (+1.57%)

USD 1.21B

ETFs Containing 6JM:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.52% 64% D 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.52% 61% D- 53% F
Trailing 12 Months  
Capital Gain -15.38% 59% D- 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.38% 56% F 28% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.62% 39% F 17% F
Dividend Return -13.62% 35% F 16% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.13% 79% B- 66% D+
Risk Adjusted Return -71.22% 29% F 15% F
Market Capitalization 1.93B 90% A- 67% D+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.